Preterm birth is a leading cause of neonatal mortality in the US and globally, with preterm premature rupture of fetal membranes (PPROM) accounting for one third of preterm births. Currently no predictive diagnostics are available to precisely assess risk and potentially reduce the incidence of PPROM. Bigycan and decorin, the main proteoglycans present in human fetal membranes, are involved in the physiological maturation of fetal membranes as well as in the pathophysiology of preterm birth. The serum protein sex hormone-binding globulin (SHBG) has recently been identified as a predictor of spontaneous preterm birth. We hypothesize that the balance between serum decorin and biglycan on one hand and SHBG on the other hand may provide insight into the status of the fetal membranes in early pregnancy, thereby predicting PPROM prior to symptoms. Using chart review, 18 patients with confirmed cases of PPROM were identified from 2013-2016. Second trimester residual serum was retreived from freezer storage for these cases along with 5 matched controls for each case. The biomarkers biglycan, decorin and SHBG were analyzed first separately, then in combination to determine their ability to predict PPROM. The predictive score for the combined model displays an AUC = 0.774. The ROC curve of the predicted score has an optimal threshold of 0.238 and a sensitivity and specificity of 0.72 and 0.84 respectively. This prenatal serum panel is a promising serum screening-based biochemical model to predict PPROM in asymptomatic women.
GoldenbergRLCulhaneJFIamsJDRomeroR. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75–84.
2.
World Health Organization. Born too Soon; The Global Action Report on Preterm Birth. Geneva, Switzerland: World Health Organization: March of DImes, PMNCH, Save the Children; 2012.
3.
MurphySLXuJKochanelKD. Deaths: Preliminary Data for 2010. U.S. Melbourne, Australia: Dept Health and Human Services; 2012.
4.
MercerB. Preterm premature rupture of the membranes. Obstet Gynecol. 2003;101(1):178–193.
5.
MingioneMJPressmanEKWoodsJR. Prevention of PPROM: current and future strategies. J Matern Fetal Neonatal Med. 2006;19(12):783–789.
6.
TchirikovMS-LMaherJBuchmannJNaberezhnevYWinarnoASSeligerG. Mid-trimester preterm premature rupture of membranes (PPROM); etiology, diagnosis, classification, international recommendtions of treatment options, and outcome. J Perinat Med. 2018;46(5):465–488.
7.
MercerBMGoldenbergRLMeisPJ. The preterm prediction study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. Am J Obstet Gynecol. 2000;183(3):738–744.
8.
RomeroRMJChaemsaithongPChaiworapongsaT. Sterile and microgial-associated intra-amnionic inflammation in preterm premature rupture of membrane. J Matern Fetal Neonatal Med. 2015;28(12):1394–1409.
9.
BarabasAP. Ehlers-Danlos syndrome: associated with prematurity and premature rupture of foetal membranes; possible increase in incidence. Br Med J. 1966;2(5515):682–684.
10.
YenJLLinSPChenMRNiuDM. Clinical features of Ehlers-Danlos syndrome. J Formos Med Assoc. 2006;105(6):475–480.
11.
QuentinEGladenARodenLKresesH. A genetic defect in the biosynthesis of dermatan sulfate proteoglycan: galactosyltransferase 1 deficiency in fibroblasts from a patient with a progeroid syndrome. Proc Natl Acad Sci U S A. 1990;87(4):1342–1346.
12.
AmeyeLYoungMF. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, oseoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology. 2002;12(9):107R–116R.
13.
WestermannDMersmannJMelchiorA. Biglycan is required for adaptive remodeling after myocardial infarction. Circulation. 2008;117(10):1269–1276.
14.
ZhangGChenSGoldoniS. Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan. J Biol Chem. 2009;284(13):8888–8897.
15.
SchaeferLBabelovaAKissE. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest. 2005;115(8):2223–2233.
16.
ParrySStraussJF. Premature rupture of the fetal membranes. N Engl J Med. 1998;338(10):663–670.
17.
de Miranda de AraujoLBHorganCEAronAIozzoRVLechnerBE. Compensatory fetal membrane mechanisms between biglycan and decorin in inflammation. Mol Reprod Dev. 2015;82(5):387–396.
18.
MeinertMMalmströmAPetersenACEriksenGVUldbjergN. Chorioamnionitis in preterm delivery is associated with degradation of decorin and biglycan and depletion of hyaluronan in fetal membranes. Placenta. 2014;35(8):546–551.
19.
HorganCERoumimperHTuckerRLechnerBE. Altered decorin and Smad expression in human fetal membranes in PPROM. Biol Reprod. 2014;91(5):105,101–107.
20.
CalmusMLMacksoudEETuckerRIozzoRVLechnerBE. A mouse model of spontaneous preterm birth based on the genetic ablation of biglycan and decorin. Reproduction. 2011;142(1):183–194.
21.
WuZHorganCECarrOOwensRTIozzoRVLechnerBE. Biglycan and decorin differentially regulate signaling in the fetal membranes. Matrix Biol. 2014;35:266–275.
22.
SaadeGRBogessKASullivanSA. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;21(4):633e631–633e624.
SavitzDDoleNHerringA. Should spontaneous and medically indicated preterm births be separated for studying aetiology?Paediatr Perinat Epidemiol. 2005;19(2):97–105.
25.
DuttaEHBehniaFBoldoghI. Oxidative stress damage-associated molecular signaling pathways differentiate spontaneous preterm birth and preterm premature rupture of the membranes. Mol Hum Reprod. 2016;22(2):143–157.
26.
MenonRRichardsonLS. Preterm prelabor rupture of the membranes: a disease of the fetal membranes. Semin Perinat. 2017;41(7):409–419.
27.
DeLongEDeLongDMClarke-PearsonDL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.
28.
FreyHSchroederNManon-JensenTIozzoRVSchaeferL. Biological interplay between proteoglycans and their innate immune receptors in inflammation. FEBS J. 2013;280(10):2165–2179.
29.
MorethKIozzoRVSchaeferL. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle. 2012;11(11):2084–2091.
30.
Zeng-BrouwersJBeckmannJNastaseM-VIozzoRVSchaeferL. De novo expression of circulating biglycan evokes an innate inflammatory tissue response via MyD88/TRIF pathway. Matrix Biol. 2014;35:132–142.
31.
NastaseMVYoungMFSchaeferL. Biglycan: a multivalent proteoglycan providing structure and signals. J Histochem Cytochem. 2012;60(12):963–975.
32.
IozzoRVSchaeferL. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 2010;277(19):3864–3875.
33.
AppunniSAnandVKhandelwalMSethAMathurSSharmaA. Altered expression of small leucine-rich proteoglycans (decorin, biglycan and lumican): plausible diagnostic marker in urothelial carcinoma of bladder. Tumour Biol. 2017;39(5):1–10.
34.
XuYZYangZGZhangYHZhangYWHongBLiuJM. Dynamic reduction of plasma decorin following ischemic stroke: a pilot study. Neurochem Res. 2012;37(9):1843–1848.
35.
WuI-CWuD-CHuangC-C. Plasma decorin predicts the presence of esophageal squamous cell carcinoma. Int J Cancer. 2010;127(21):2138–2146.
36.
CaglarMYavuzcanAGoksuM. Decorin: a possible marker for fetal growth restriction. Gynecol Endocrinol. 2014;30(2):141–144.
37.
AtalayMAOzmenTDemirBCKasapogluIOzkayaG. Serum decorin measurement in prediction of the risk for preterm birth. Taiwan J Obstet Gynecol. 2018;57(1):23–27.
38.
YuCKPapageorghiouATBindaRSpencerKNicolaidesKH. Second-trimester sex hormone-binding globulin and subsequent development of pre-eclampsia. J Matern Fetal Neonatal Med. 2004;16(3):158–162.
39.
SpencerKYuCKRembouskosGBindraRNicolaidesKH. First trimester sex hormone-binding globulin and subsequent development of preeclampsia or other adverse pregnancy outcomes. Hypertens Pregnancy. 2005;24(3):303–311.
40.
Herrera-MunozAFernandez-AlonsoAMFischer-SuarezNChedrauiPPerez-LopezFR. Maternal serum cytokine levels in pregnancies complicated with threatened preterm labor. Gynecol Endocrinol. 2017;33(5):408–412.
41.
Kansu-CelikHTasciYKarakayaBKCinarMCandarTCaglarGS. Maternal serum advanced glycation end products level as an early marker for predicting preterm labor/PPROM: a prospective study. J Matern Fetal Neonatal Med. 2018;22:1–5.
42.
ChenWZhangYYueC. Accumulation of advanced glycation end products involved in inflammation and contributing to severe preeclampsia in maternal blood, umbilical blood and placental tissues. Gynecol Obstet Invest. 2017;82(4):388–397.
43.
HongXHaoKJiH. Genome-wide approach identifies a novel gene-maternal pre-pregnancy BMI interaction on preterm birth. Nat Commun. 2017:1–9.
44.
TorloniMRBetranAPDaherS. Maternal BMI and preterm birth: a systematic review of the literature with met-analysis. J Matern Fetal Neonatal Med. 2009;22(11):957–970.
45.
ShawGMWisePHMayoJCarmichaelSLLeyCLyellDJ. Maternal prepregnancy body mass index and risk of spontaneous preterm birth. Paediatr Perinat Epidemiol. 2014;28(4):302–311.
46.
AndraweeraPHDekkerGAThompsonSD. The interaction between the maternal BMI and angiogenic gene polymorphisms associates with the risk of spontaneous preterm birth. Mol Hum Reprod. 2012;18(9):459–465.
